Simcere Of China Says New Use Of Biotech Endu Favorable
This article was originally published in PharmAsia News
China's Simcere Pharmaceuticals said its Endu, an endostatin biotech drug already approved for treating lung cancer, has demonstrated in interim results it is safe when used with platinum-containing chemotherapy. China's State FDA sought a re-evaluation of the drug before it would grant the new indication. Simcere said the new trial, expected to be completed in 2010, appears to show the drug is well-tolerated with chemotherapy. (Click here for more
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.